Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 24;12(11):3639.
doi: 10.3390/jcm12113639.

Steroids in Lupus: Enemies or Allies

Affiliations
Review

Steroids in Lupus: Enemies or Allies

Eugenia Enríquez-Merayo et al. J Clin Med. .

Abstract

Glucocorticoids are the gold standard treatment for reducing immune activation and inflammation in a wide range of inflammatory and systemic autoimmune diseases. Glucocorticoids have potent and fast actions that quickly relieve some symptoms and lower mortality in some life-threatening conditions, but they also have side effects that limit the duration of treatment and the dose used. Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the involvement of numerous organs and systems and the production of autoantibodies. Most current treatments include the use of corticosteroids and immunosuppressive medications. Glucocorticoids in SLE have been classically used not only to induce remission or treat an acute situation but also as maintenance therapy. During the last decades, new approaches to managing SLE have emerged, but corticosteroids continue to be part of all therapeutic regimes. There is more and more evidence about the side effects related to the use (or abuse) of steroids and their relationship with the accrual damage. In this manuscript, we try to make a critical review of the published literature about the benefit and side effects/damage that can be attributed to the use of glucocorticoids.

Keywords: acrual damage; dose; side effectis; treatment duration.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Kyttaris V.C., Krishnan S., Tsokos G.C. Systems biology in systemic lupus erythematosus: Integrating genes, biology and immune function. Autoimmunity. 2006;39:705–709. doi: 10.1080/08916930601061363. - DOI - PubMed
    1. Stahn C., Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat. Clin. Pract. Rheumatol. 2008;4:525–533. doi: 10.1038/ncprheum0898. - DOI - PubMed
    1. Strehl C., Buttgereit F. Unraveling the functions of the membrane-bound glucocorticoid receptors: First clues on origin and functional activity: Unraveling the secret of the mGRs. Ann. N. Y. Acad. Sci. 2014;1318:1–6. doi: 10.1111/nyas.12364. - DOI - PubMed
    1. Buttgereit F., da Silva J.A.P., Boers M., Burmester G.-R., Cutolo M., Jacobs J., Kirwan J., Köhler L., van Riel P.L.C.M., Vischer T., et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: Current questions and tentative answers in rheumatology. Ann. Rheum. Dis. 2002;61:718–722. doi: 10.1136/ard.61.8.718. - DOI - PMC - PubMed
    1. Schäcke H., Döcke W.D., Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 2002;96:23–43. doi: 10.1016/S0163-7258(02)00297-8. - DOI - PubMed

LinkOut - more resources